Theoretically, PD-L1 expression is the most direct marker for predicting the efficacy of PD-1/PD-L1 inhibitors, but unlike other malignancies, HCC is often accompanied by hepatitis or cirrhosis, which makes the tumor microenvironment of HCC more complex. This evidence concerns the gene PDCD1 and Cirrhosis.